EASL International Liver Congress 2018

Published on 13/02/2018

April 11-15, 2018

Paris, France

ENYO Pharma is proud to announce that its Poster has been selected to be presented at EASL International Liver Congress in Paris on April 11-15th. The company team will present its latest Hepatitis B studies and data about its EYP001 compound (FXR agonist) developed for chronic hepatitis B patients. The annual Congress, which aim at presenting the latest topics in liver research, will be a great opportunity for the company as more than 10,000 delegates and 250 media representatives from all over the world will participate. (https://ilc-congress.eu)
Poster EASL ILC 2018

Read next in 'Events'

• The 2024 international workshop on Alport syndrome
• ENYO Pharma annonce un financement de Série C de 39 millions d'euros et l’autorisation de la FDA (IND) pour tester Vonafexor dans un essai clinique de Phase 2 pour les patients atteints du syndrome d'Alport
• 6th CKD Summit – Chronic Kidney Disease Drug Development
• ASN Kidney Week
• Alport Connect 2023, the annual Alport syndrome patient and family meeting in US